This demonstrates that HCC tumors, progressing on HCV, NAFLD and NASH affected livers and for which ChREBP expression is elevated, accumulated on the higher risk side. The gene discussed is MLXIPL; the disease is metabolic dysfunction-associated steatotic liver disease.